Repligen Q4 revenue $198M (+18%); FY26 guidance $810-840M

REPLIGEN CORP

2025-FY EPS reported $0.86 revenue$738,256,000

Q4 revenue $198M, up 18% reported and 14% organic YoY; full year 2025 revenue $738M (+16% reported and organic non-COVID).
Q4 GAAP EPS $0.23 vs ($0.60); adjusted EPS $0.49 vs $0.44. Full year adjusted EPS $1.71 vs $1.58.
FY26 revenue guidance $810M–$840M (10-14% reported, 9-13% organic); adjusted operating margin expansion of 150 bps at midpoint.
Full year 2025 organic growth of 14% exceeded initial guidance range; adjusted operating margins improved 90 bps YoY.
CEO cited strong finish led by Analytics and Proteins; new office in Singapore and product launches in Q4.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.